Literature DB >> 4065251

Aberrant melanosome development in the retinal pigmented epithelium of cats with Chediak-Higashi syndrome.

L L Collier, E J King, D J Prieur.   

Abstract

The Chediak-Higashi syndrome is a genetic disorder characterized by greatly enlarged cytoplasmic granules, including lysosomes and melanosomes. Eyes of humans and animals with Chediak-Higashi syndrome are hypopigmented to various degrees. Intraocular melanin granules vary in size, with some being massively enlarged. Electron microscopic examination of retinal pigmented epithelium of kittens with Chediak-Higashi syndrome disclosed a number of abnormalities of premelanosomes and melanosomes. Few premelanosomes were present. Most of the melanin granules were giant sized, but their structures varied. Some of the giant granules were composed of several premelanosomes and melanosomes in different stages of maturation. Others contained randomly oriented melanofilaments between melanosomes. There were also complex giant granules consisting of both melanosomal and lysosomal components. Inappropriate fusion of cytoplasmic granules appears to be the most likely mechanism for formation of the giant granules. Fusion of premelanosomes with lysosomes and resultant destruction of the premelanosomes probably is a major cause of the ocular hypopigmentation of Chediak-Higashi syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065251     DOI: 10.1016/s0014-4835(85)80021-x

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  2 in total

1.  Dictyostelium LvsB has a regulatory role in endosomal vesicle fusion.

Authors:  Kristin Falkenstein; Arturo De Lozanne
Journal:  J Cell Sci       Date:  2014-08-01       Impact factor: 5.285

2.  Selective Ablation of Megalin in the Retinal Pigment Epithelium Results in Megaophthalmos, Macromelanosome Formation and Severe Retina Degeneration.

Authors:  Tina Storm; Thomas Burgoyne; Joshua L Dunaief; Erik I Christensen; Clare Futter; Rikke Nielsen
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-01-02       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.